Select Page
Soin Therapeutics receives FDA Orphan Drug Status Grant

Soin Therapeutics receives FDA Orphan Drug Status Grant

The US FDA (Food and Drug Administration) has granted Ohio-based pharmaceutical company Soin Therapeutics orphan drug status for low dose naltrexone (LDN) for the treatment of complex regional pain syndrome (CRPS). Complex Regional Pain Syndrome is characterized by...
Eagle Receives USPTO Additional Patent for Bendamustine

Eagle Receives USPTO Additional Patent for Bendamustine

Eagle Pharmaceuticals have been granted their U.S. Patent No. 11,103,483 titled, “Formulations of Bendamustine”, by the U.S. Patent and Trademark Office (USPTO). Eagle plans to submit this patent to be included in the FDA’s (Food and Drug Administration’s) Orange Book...